Kerala SMA drug controversy impacts CPI-M political standing

A controversy regarding the supply of an Indian-made drug for children with Spinal Muscular Atrophy (SMA) has created political tension in Kerala. The CPI-M, which criticized the current government over the procurement of generic medicines, is facing scrutiny following reports that a technical committee had previously recommended the drug manufactured by Natco.

Documents suggest that the State Nodal Officer appointed during the previous LDF government tenure had communicated regarding the medicine, complicating the CPI-M’s attempt to place sole responsibility on the current UDF government. Former Health Minister Veena George raised concerns regarding the manufacturing dates, quality certification, and the use of medicines labeled for clinical trials.

However, the CPI has distanced itself from the CPI-M’s stance. CPI State Secretary Binoy Viswam questioned the political propriety of the criticism, noting the global Left's position on generic medicines. The Sasthra Sahithya Parishad also backed the health department’s decision to use Natco’s low-cost generic version, which costs approximately Rs 15,900 per bottle, compared to Roche’s branded medicine at roughly Rs 6.2 lakh per bottle.

SAT Hospital superintendent Dr. Riyaz stated that the disputed medicines were free samples supplied by the company through the Kerala Medical Services Corporation (KMSCL).